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Mesenchymal stem cells (MSCs) show great therapeutic potential for the treatment
of various immune mediated diseases, including Multiple Sclerosis (MS). Systemic
administration of MSCs during experimental allergic encephalomyelitis (EAE), an animal
model for MS, was shown to reduce the infiltration of T cells, B cells, and macrophages
into the CNS. Whether endogenous MSCs are mobilized and potentially modulate the
severity of disease is not known. Here we show that during the acute phase of EAE,
MSCs numbers in the bone marrow were severely reduced, which restored to control
levels during the progressive phase of the disease. The number of bone marrow MSCs
inversely correlated with the number of both CD4 and CD8 T cells present in the bone
marrow indicating a link between activated T cells and MSC mobilization. Analysis of
CD70-transgenic mice, which have a constitutively activated immune system and elevated
number of activated T cells in the bone marrow, showed severely reduced number of bone
marrow MSCs. Transfer of T cells that were activated through their CD27 receptor reduced
the number of bone marrow MSCs dependent on IFN-y. These data provide a mechanism
by which MSCs can be mobilized from the bone marrow in order to contribute to tissue
repair at a distant location.
Keywords: MSC mobilization, experimental allergic encephalomyelitis, inflammation and MSC, bone marrow and
MSC, MSC and IFNg, CD70
INTRODUCTION
Mesenchymal stem cells (MSCs) are described as multipotent
stromal cells, mainly residing in the bone marrow, although they
can also be found in low numbers in almost all adult tissues
(Kuznetsov et al., 2001; da Silva et al., 2006). MSCs can differen-
tiate into various cells of the mesodermal lineage which include
osteoblasts, adipocytes, and chondrocytes as well as myelosup-
portive stroma which, together with endothelial cells, are all con-
stituents of the heterogeneous bone marrow stroma (Friedenstein
et al., 1966; Kuznetsov et al., 1997; Prockop, 1997; Pittenger et al.,
1999; Tokoyoda et al., 2010). Stromal cells within the bone mar-
row support the maintenance of hematopoietic stem cells (HSCs)
(Mendez-Ferrer et al., 2010).
In the bone marrow, MSCs were identified as a popu-
lation of nestin-expressing cells which exclusively contained
colony-forming-unit fibroblast (CFU-F) activity and depletion of
nestinpos cells reduced the HSC-activity in bone marrow indicat-
ing that these cells are HSC-niche components (Mendez-Ferrer
et al., 2010). However, whereas HSCs crucially depend on stem
cell factor (SCF) produced by niche cells, deletion of SCF from
nestinpos cells did not affect HSC frequency in the bone marrow
(Ding et al., 2012), suggesting that other cell types also contribute
to HSC maintenance through SCF production. Indeed, both
endothelial as well as leptin receptor-expressing perivascular cells
were identified as the source of SCF and deletion of either popula-
tion clearly reduced HSCs numbers in bone marrow (Ding et al.,
2012). Therefore, multiple cell types within the heterogeneous
bone marrow stroma support HSC-niche maintenance under
homeostatic conditions.
In analogy to the supportive function of lymph node stro-
mal cells in immune cell homeostasis (Koning andMebius, 2011),
bone marrow stromal cells can also support maintenance of var-
ious lymphocytes (Tokoyoda et al., 2010). The lack of distinctive
structures such as lymphatic endothelial cells as well as special-
ized high endothelial venules in the bone marrow however, may
reflect differences in the functional role of these organs in lym-
phocyte homeostasis. Verily, whereas lymph node stromal cells
are involved in the initial phase of immune responses, bone mar-
row stromal cells participate in maintaining memory cells, both
plasma cells and CD4pos T cells (Tokoyoda et al., 2010). Memory
T cells reside in contact with VCAM-1pos stromal cells that express
IL-7, a T cell survival cytokine (Fry and Mackall, 2005; Tokoyoda
et al., 2009). Bonemarrow plasma cells locate near CXCL12 abun-
dant reticular (CAR) cells, while the preponderance of HSCs
also locates near CAR cells. Therefore, whereas in lymph nodes
specialized micro-environmental stromal subsets, which support
specific types of immune cells, have been described (Koning
and Mebius, 2011), such subdivisions for bone marrow stromal
cells are less well defined. Nevertheless, the overlapping support-
ive and suppressive roles of stromal cell microenvironments in
lymphocyte homeostasis and function, respectively, are shared
by all stromal cells despite distinct anatomical locations (Jones
et al., 2007). MSCs are precursors for stromal cells in various
organs, and they share immunosuppressive effects with stromal
www.frontiersin.org March 2013 | Volume 4 | Article 49 | 1
Koning et al. Inflammation mobilizes bone-marrow stromal precursors
cells. Therefore, MSCs are thought to serve as good candidates
to treat immune mediated diseases including Multiple Sclerosis
(MS) (Uccelli et al., 2008).
MS is a chronic inflammatory disease resulting in demyeli-
nation and axonal loss throughout the central nervous system
(CNS), with unknown cause and only limited treatment options
(Ewing and Bernard, 1998; Noseworthy et al., 2000; Lassmann
et al., 2001). Spontaneous remyelination that contributes to func-
tional recovery is limited resulting in a relentless increase in dis-
ability during disease progression (Scolding and Franklin, 1998;
Bruck et al., 2003; Fancy et al., 2010).
The effectiveness of administration of MSCs for treatment of
MS patients needs to be explored in more detail, but animal
studies in rodents show promising perspectives for future treat-
ments. The most commonly used animal model for MS research
is murine experimental allergic encephalomyelitis (EAE). This
model resembles both the inflammatory phase, i.e., the gen-
eration of autoreactive myelin specific T cells, as well as the
neurodegenerative phase of the disease, i.e., destruction of the
myelin sheath around the axons and subsequent loss of axons,
as observed in human disease (Steinman, 2001). Several stud-
ies have shown that systemic administration of MSCs at disease
onset ameliorated EAE and decreased infiltration of T cells, B cells
and macrophages into the CNS (Zappia et al., 2005; Kassis et al.,
2008). In these studies MSCs exerted immunomodulatory effects
via inhibition of T cell activation and proliferation.
A recent study indicates that MSCs also harbor direct neu-
roprotective effects. It was demonstrated that administration of
MSCs at the onset of EAE remarkably reduced the levels and
activity of anti-oxidant molecules in vivo (Lanza et al., 2009).
Subsequently, using an in vitromodel system, the authors showed
that upon induction of oxidative stress within a neuroblastoma
celline, MSC-conditioned medium suppressed the upregulation
of anti-oxidant molecules indicating a direct neuroprotective
effect of MSCs (Lanza et al., 2009).
While it was shown that MSCs migrate to the brain upon i.v.
administration after the experimental induction of stroke, only a
small percentage of these cells enters the CNS parenchyma (Eglitis
et al., 1999). And although MSCs were reported to transdifferen-
tiate in vitro into neural cells (Kopen et al., 1999) most studies
so far indicate that MSCs do not transdifferentiate in vivo during
EAE, despite their presence in spinal cord (SPC) and brain after
systemic administration (Zappia et al., 2005; Gerdoni et al., 2007).
Therefore, the positive effect of MSC administration on the dis-
ease course of EAE is mostly through modulation of immune cells
although direct neuroprotective effects may also play a role.
All studies which addressed a potential therapeutic effect of
MSCs on EAE disease outcome focused on administration of
exogenous MSCs (Zappia et al., 2005; Gerdoni et al., 2007; Kassis
et al., 2008; Lanza et al., 2009). However, so far there is no
data concerning the behavior of endogenous MSCs during the
course of EAE. Since the bone marrow is the major source
of MSCs, we investigated the presence of bone marrow MSCs
during the course of MOG induced EAE. We found severely
reduced numbers of bone marrow MSCs at the peak of dis-
ease, which restored to control levels upon progression into the
chronic phase. Activated CD4 T cells in the CNS, which produce
pro-inflammatory molecules such as IFN-y, TNF-α, IL-17, lym-
photoxin, and GM-CSF, are considered to play a central role in
the pathogenesis of MS and EAE (Zamvil and Steinman, 1990;
Sospedra and Martin, 2005; Segal, 2010; Codarri et al., 2011).
Analysis of the immune cells within the bone marrow revealed
a significant negative correlation between CD4pos and CD8pos T
cells and MSC, such that high numbers of either T cell subset
coincided with low numbers of bone marrow MSCs, suggesting
a T cell mediated effect on MSC mobilization. Analysis of MSC
numbers in the bone marrow of mice with constitutively acti-
vated T cells showed a strong reduction of MSCs in the bone
marrow. Indeed, transfer of T cells, which were subsequently acti-
vated through their CD27 receptor, demonstrates a role for T cells
in reducing the number of MSCs. While prolonged production of
IFN-y in the bone marrow seemed to reduceMSC numbers, short
term mobilization by T cells was independent of T cell derived
IFN-y.
RESULTS
REDUCED NUMBER OF MESENCHYMAL STEM CELLS IS PRESENT IN
THE BONE MARROW DURING EAE
Over the past years there has been increasing evidence that
administration of MSCs decreases the severity of EAE (Zappia
et al., 2005; Kassis et al., 2008; Lanza et al., 2009). However, so far
no data has been presented concerning the behavior of endoge-
nous bone marrow MSCs during the course of EAE. Therefore,
we induced EAEwith recombinantmyelin oligodendrocyte glyco-
protein (rMOG) and analyzed total numbers of MSCs in the bone
marrow, the major reservoir forMSCs, at various timepoints after
disease induction (day 8, 15, and 29). At day 8 after disease induc-
tion, mice are still in the inductive phase and exhibit no clinical
signs yet. However, at day 15 after disease induction, mice suffered
from severe clinical signs varying from hind leg bending (score 2)
to complete hind leg paralysis (score 4) which is accompanied
by infiltration of immune cells, such as macrophages as well as
T cells, in white matter lesions of the brain (Kooij et al., 2009).
During the progressive phase of the disease (day 29), clinical
symptoms were slightly improved (Figure 1A).
Total numbers of MSC, present in the bone marrow, were
determined using the colony-forming units-fibroblast (CFU-F)
assay, which exploits specialized medium to allow selective out-
growth of MSCs. At day 8, shortly before clinical onset of the
disease, no change in the amount of bone marrow MSCs could
be observed when compared to CFA induced control animals
(Figure 1B). Strikingly, at the peak of the disease (day 15), we
observed a dramatic reduction in the amount of MSCs present
in the bone marrow (Figure 1B). This decrease in bone marrow
MSCs appeared to be transient, since numbers were comparable
to control mice at the chronic phase (day 29), when clinical symp-
toms started to improve (Figures 1A,B). In mice that exhibit no
clinical symptoms despite disease induction, we could not observe
changes in MSC numbers (data not shown).
The decrease in absolute numbers of MSC at day 15 was not
the result of a decrease in bone marrow cellularity, since total
bone marrow cell counts were comparable to CFA control mice
(Figure 1C). Bone marrow MSCs are precursors for bone mar-
row mesenchymal stromal cells and although it appeared that
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FIGURE 1 | Continued
FIGURE 1 | The number of MSCs decreases transiently in the bone
marrow during EAE. (A) Clinical signs of rMOG (1–125) induced EAE
showing mean clinical scores (± SEM). Mice were examined daily for
clinical signs of EAE and were scored as followed: 0, no disease; 1, limp
tail; 2, hind limb weakness; 3, complete hind limb paralysis; 4, hind limb
paralysis plus forelimb paralysis; and 5, moribund or dead. Bone marrow
was isolated at day 8, 15, and 29 after immunization as indicated by arrows
(n = 3 per group). (B) Numbers of MSCs present in the bone marrow
during the course of EAE analyzed at the indicated timepoints after EAE
induction. Total numbers of MSCs were determined by colony forming unit
(CFU) assay and numbers of CFUs are expressed as mean ± SEM (n = 3 or
more per group, one way ANOVA, ∗p < 0.05). (C,D) Bone marrow cell
counts and total number of CD45neg cells of EAE mice during the course of
EAE analyzed at the indicated timepoints. Data represent mean ± SEM of
EAE induced mice (n = 3 or more per group).
MSCs were mobilized from the bone marrow, it is conceivable
that MSCs have differentiated locally into bone marrow mes-
enchymal stromal cells, thus remaining within the bone marrow.
To address whether the number of bone marrow stromal cells had
increased, the total number of CD45neg cells in the bone marrow
was determined by FACS analysis at day 8, 15, and 29 after disease
induction. These analyses showed no significant changes, suggest-
ing that the stromal compartment did not expand substantially
(Figure 1D). These data suggest that MSCs are mobilized from
the bone marrow during the course of EAE.
THE NUMBER OF MSCs NEGATIVELY CORRELATES WITH BOTH CD4
AND CD8 T CELLS DURING EAE
Mobilization of MSCs is a multistep process, in which the initial
release from their niche is followed by active migration of MSCs
across bone marrow endothelium to eventually reach the blood-
stream (Pitchford et al., 2009). The factors involved in mobi-
lization of MSCs are not completely elucidated but it has been
shown that treatment with VEGF followed by CXCR4-antagonist
infusion leads to mobilization of MSCs out of the bone marrow
(Pitchford et al., 2009). Recombinant-MOG-induced EAE is pri-
marily a T cell mediated disease (Zamvil and Steinman, 1990),
although the disease additionally involves other immune cells
(Hemmer et al., 2002). These immune cells may in fact migrate
to the bone marrow, where they could mediate the mobilization
of MSCs. We therefore analyzed the composition of the immune
cells in bone marrow with FACS analysis during the course of
the disease and correlated the number of immune cells with the
number of MSCs present in the bone marrow. Interestingly we
observed a significant negative correlation between the num-
ber of both CD4pos and CD8pos T cells and MSCs, such that
high number of T cells correlated with low numbers of MSCs
(Figures 2A,B), independent of time after induction of the dis-
ease. We did not observe such a correlation with B cells, dendritic
cells, granulocytes, or macrophages (Figures 2C–F).
Therefore, we hypothesized that activated T cells that migrate
to the bone marrow during the course of EAE may in fact be
involved in the mobilization of MSCs. Alternatively, high num-
bers of activated T cells in bone marrow samples could influence
the outcome of the CFU assays through the production of growth
factors, which may suppress MSC proliferation or induce MSC
apoptosis. To test whether activated CD4pos or CD8pos T cells
www.frontiersin.org March 2013 | Volume 4 | Article 49 | 3
Koning et al. Inflammation mobilizes bone-marrow stromal precursors
FIGURE 2 | The number of MSCs negatively correlates with both
CD4 and CD8 T cells during EAE. Absolute numbers of MSCs plotted
against the absolute numbers of (A) CD4 T cells, (B) CD8 T cells,
(C) B cells, (D) Dendritic cells, (E) Granulocytes, and (F) macrophages
during the coarse of EAE. Correlation was analyzed by using linear
regression analysis.
in general could produce factors which could inhibit the pro-
liferation of MSCs in vitro, thereby affecting the outcome of
the CFU-F assay, we cultured bone marrow MSCs of healthy
mice with supernatants of in vitro CD3-CD28 beads activated
CD4pos or CD8pos T cells. We labeled MSCs with CFSE and
cultured them for 3 days, allowed them to proliferate under
normal culture conditions, in the presence or absence of dif-
ferent concentrations of supernatants from activated CD4pos or
CD8pos T cells. Upon cell division, CFSE is equally divided over
the daughter cells and thus reduced cell division will result in
higher MFI levels of the measured CFSE. Although the super-
natants contained IFN-y and TNF-α (data not shown), indicating
that T cells were indeed activated, we observed no difference
in the capacity of MSCs to proliferate upon addition of vari-
ous concentrations of supernatant derived from activated CD4pos
T cells when compared to MSCs cultured under normal condi-
tions (Figure 3A). The same results were obtained with super-
natants from activated CD8pos T cells (Figure 3A). Furthermore,
culturing CFSE labeled MSCs with different concentrations of
various recombinant cytokines, inflammatory molecules, growth
factors and potential mobilization factors, revealed that none of
these factors substantially inhibited the proliferation of MSCs
in vitro (Figure 3B). Together, these data indicate that factors
produced by activated T cells did not directly affect the pro-
liferation of MSCs and therefore did not influence our CFU
assays. Consequently, our data suggest that other mechanisms are
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FIGURE 3 | Proliferation of MSCs not affected upon cytokine treatment.
(A,B) In vitro proliferation of CFSE labeled bone marrow derived MSCs from
healthy mice in the presence of different concentrations of supernatants
from CD3/CD28 beads activated CD4 or CD8 T cells (A) or various growth
factors or cytokines (B) during 72h measured by MFI of CFSE. Experiments
were performed three times in duplo and a representative example is shown.
(C) TNF-alpha and VEGF-A levels determined by Luminex assay in
supernatants of bone marrow samples which were re-stimulated in vitro with
rMOG for 72 h. Experiments performed in duplo and data represent fold
change compared to CFA induced control mice (n = 3 per group).
(D) Absolute numbers of MSCs in cervical lymph nodes and spinal cord in
EAE animals at day 29 after immunization (n = 3, mean ± SEM).
involved in the observed decrease in numbers of MSC in the bone
marrow during the course of EAE.
To test whether T cells present in the bone marrow produce
inflammatory mediators that could instigate the mobilization of
MSCs, we determined whether TNF-α, IFN-y, and IL-17 could
be detected in supernatants of complete bone marrow samples
upon in vitro restimulation with rMOG for 72 h. Surprisingly, res-
timulation did not result in detectable levels of IFN-y or IL-17
(data not shown) and only low levels of TNF-α, which was ele-
vated at day 29 when compared to control bone marrow samples,
could be detected (Figure 3C). Since VEGF-A has been shown
to be directly involved in mobilization of MSCs from the bone
marrow (Pitchford et al., 2009) and CD4pos T cells are able to
produce VEGF-A upon activation (Matsuyama et al., 2002), we
also determined the levels of VEGF-A in these supernatants. Even
though detectable levels of VEGF-A could be measured, we did
not observe increased VEGF-A levels in bone marrow samples
derived from EAE mice when compared to controls, which could
account for the mobilization of MSCs (Figure 3C).
Since we showed that the number of bone marrow MSCs is
transiently decreased during the course of EAE, we addressed
whether these cells could be found at elevated numbers at other
locations in the body. We could detect CFU-F activity only in the
meninges of EAE mice, and not in control animals, at day 15 after
disease induction, although the numbers of precursors were very
low (data not shown). In addition, we determined the numbers
of MSCs in SPC, and cervical lymph nodes (cLNs) of mice at the
chronic phase of EAE (day 29), however, CFU-F analysis of cLNs
as well as SPC did not reveal significant differences (Figure 3D).
Collectively, the observed decrease of MSCs within the bone
marrow of diseased animals is paralleled by an increase of T cells
within the bonemarrow. Since inflammatory mediators could not
be identified as the responsible effector molecules, direct cell-cell
contact between CD4pos or CD8pos T cells and MSCs within the
bone marrow could regulate the number of bone marrow MSCs
during the course of EAE.
IFN-y MEDIATED CHRONIC IMMUNE ACTIVATION DEPLETES MSCs IN
BONE MARROW
To address whether activated T cells could indeed affect the
presence of MSCs in the bone marrow during chronic immune
activation, we analyzed the number of MSCs in the bone mar-
row of B cell specific CD70 transgenic (CD70TG) mice. These
mice have a constitutively activated T cell compartment since
transgenic over-expression of CD70 by B cells induces T cells to
continuously produce high levels of IFN-y, eventually leading to
depletion of B cells from bone marrow, spleen, and lymph nodes
(Arens et al., 2001; de Bruin et al., 2010). When these mice are
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crossed with IFN-y−/− mice, B cell numbers remain normal when
compared to IFN-y−/− mice, indicating that constitutive produc-
tion of IFN-y by T cells induces B cell depletion (Arens et al.,
2001). In addition, B cell depletion is also a result of extensive
triggering of CD27 expressed on hematopoietic precursors (Nolte
et al., 2005).
Analysis of the amount of MSCs present in the bone marrow
of CD70TGmice revealed a strong reduction in absolute numbers
of MSCs when compared to WT controls. Strikingly, this effect
was eliminated when CD70TG mice were crossed to IFN-y−/−
mice (Figure 4A). It has been reported that CD70TGIFN-y−/−
mice still showed an activated T cell compartment as indicated
FIGURE 4 | Chronic immune activation depletes MSCs from the bone
marrow. (A) Absolute numbers of MSCs in bone marrow in WT, CD70TG,
and CD70TG/IFN-y−/− mice. (B) Total cell count, and (C) absolute numbers
of CD45neg cells in bone marrow of WT, CD70TG, and CD70TG/IFN-y−/−
mice. Data represent mean ± SEM of 3 animals per group (ANOVA;
∗p < 0.05).
by increased numbers of CD44hiCD62Lneg T cells in both lymph
nodes and bone marrow (Arens et al., 2001; de Bruin et al., 2010),
therefore, it is unlikely that the observed decrease in bone marrow
MSCs in CD70TG mice is a result of the presence of activated T
cells but rather highlights the role of IFN-y produced by T cells in
reducing the number of MSCs in the bone marrow. Additionally,
the observed differences were neither the result of changes in bone
marrow cellularity nor differentiation of MSCs into stromal cells,
as we observed no changes in total cell count or the amount of
CD45neg cells in CD70TG mice, respectively (Figures 4B,C).
MOBILIZATION OF MSCs DEPENDS ON T CELL DERIVED IFN-y
To more clearly indicate that indeed IFN-y producing activated T
cells are responsible for the reduction ofMSC in the bone marrow
we adoptively transferred WT T cells into CD70TGxCD27−/−
mice. Upon transfer, only the donor T cells will become acti-
vated through CD27-CD70 interaction, while they subsequently
differentiate into effector T cells (Figures 5A,B) and accumu-
late in the bone marrow. Transfer of WT T cells clearly reduces
absolute number of MSCs within 3 weeks when compared to
CD70TGxCD27−/− mice (Figure 5D). To assess whether this
effect is IFN-y mediated, we also adoptively transferred IFN-y−/−
T cells into CD70TGxCD27−/− mice. The transfer of an equal
amount of IFN-y−/− T cells was not sufficient to reduce num-
ber of MSCs within the same time period (Figure 5D). Transfer
of WT T cells or IFN-y−/− T cells did not affect bone marrow
cellularity (Figure 5D). Strikingly, we observed increased num-
bers of CD8 T cells but not CD4 T cells in the bone marrow of
CD70TGxCD27−/− that received WT T cells (Figure 5C).
Upon analysis of MSC number after 5 days of transfer of
WT T cells or IFN-y−/− T cells we did not observe differences
between the two groups (data not shown) suggesting that the
reduction of MSCs depends on prolonged T cell activation and
IFN-y production.
Together, these data indicate that mobilization of MSC out of
the bone marrow is mediated via IFN-y production by activated
T cells.
DISCUSSION
MSCs have emerged as potential therapeutic treatment of MS,
since they possess strong immunosuppressive capacity. In EAE,
the most commonly used animal model for MS, it was shown that
transfer of MSCs before or at the onset of clinical disease, reduced
the clinical signs of the disease. By suppressing immune cell acti-
vation and thereby the infiltration of immune cells into the CNS,
the administration MSCs resulted in reduced demyelination and
axonal loss (Zappia et al., 2005; Gerdoni et al., 2007; Kassis et al.,
2008; Lanza et al., 2009). Here we addressed whether endogenous
MSCs could affect the ongoing disease. MSCs can be found in
almost all organs, but they are most frequent in bone marrow
(da Silva et al., 2006). We observed a strong reduction in the
amount of bone marrow MSCs at the peak of the disease, which
returned to control levels during the chronic phase of the disease.
We hypothesize that this strong reduction in bone marrow MSCs
is due to mobilization of MSCs into the periphery. Analysis of
the hematopoietic compartment revealed that high levels of both
CD4pos and CD8pos T cells coincided with low numbers of MSCs
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FIGURE 5 | Mobilization of MSCs depends on T cell derived IFN-y.
(A,B) Phenotype of WT and IFN-y−/− donor CD4 and CD8 T cells before
adoptive transfer (A) and phenotype of donor WT T cells and host donor T
cells in the bone marrow of CD70TGxCD27−/− mice after 3 weeks of
adoptive transfer (B), effector memory; CD44posCD62Lneg, central
memory; CD44posCD62Lpos, naive; CD44negCD62Lpos. (C) Absolute
numbers of CD8 or CD4 T cells in bone marrow of CD70TGxCD27−/−
recipients that received no T cells, WT T cells or IFN-y−/− T cells.
(D) Absolute numbers of MSCs and total cell count in bone marrow of
CD70TGxCD27−/− recipients that received no T cells, WT T cells or
IFN-y−/− T cells. Data represent an average of 5 animals per group
(±SEM, ANOVA, ∗p < 0.05, ∗∗p < 0.01).
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in the bone marrow. We propose that upon inflammation, acti-
vated T cells, which migrate to the bone marrow, can mediate the
mobilization of MSCs in an IFN-y dependent way.
Several factors have been proposed to mediate the mobiliza-
tion of MSCs from the bone marrow. For instance, elevated levels
of MSCs are found within 48 h in peripheral blood after exper-
imentally induced femoral vascular injury. The mobilization of
MSCs from the bone marrow in this model is possibly mediated
by VEGF and G-CSF, since these factors were significantly ele-
vated within 24 h (Wang et al., 2008). Others have shown that
combined treatment of mice with VEGF and G-CSF is not suf-
ficient to mobilize MSCs, but that interrupting the SDF1-CXCR4
axis together with VEGF pretreatment is mandatory for MSC
mobilization (Pitchford et al., 2009). In both studies, mobiliza-
tion is not mediated by immune cells and in the latter study, mice
were not exposed to tissue injury.
Under normal, non-pathogenic conditions, the bone marrow
harbors both memory T cells together with T cells that continu-
ously circulate through the body. Additionally, the bone marrow
also functions as a secondary lymphoid organ, since priming of
naïve T cells can take place within the bonemarrow (Feuerer et al.,
2003). Moreover, the bone marrow can actively recruit activated
T cells which is mediated through alpha 2-integrin (Di Rosa and
Pabst, 2005; Tokoyoda et al., 2009). We hypothesized that acti-
vated T cells present in the bone marrow could influence the
number of bone marrow MSCs. To test this, we analyzed B cell
specific CD70TG mice, which contain T cells that are constitu-
tively activated and produce IFN-y continuously. As a control
we used CD70TGxIFN-y−/− mice, which still have an activated
T cell compartment, but lack the production of IFN-y (Arens
et al., 2001). Whereas in CD70TG mice, numbers of MSCs were
severely reduced, this phenomenon was completely abrogated in
CD70TG mice that were deficient for IFN-y, demonstrating that
the reduced MSC numbers were a result of continuous IFN-y
production in the bone marrow, most likely derived from acti-
vated T cells. Activated T cells express the adhesion molecule
CD44, which serves as a ligand for hyaluronic acid that colocalizes
with CXCL12, produced in the bone marrow by both endothe-
lial cells and stromal cells including MSCs (Avigdor et al., 2004).
Therefore, during immune activation, T cells could specifically
localize close to MSCs, secrete IFN-y locally, thereby mediating
MSC mobilization. Since the CD70TGxIFN-y−/− mice still con-
tain an activated T cell compartment, including CD44 expressing
activated T cells, it is unlikely that mobilization of MSCs is
caused only through physical interaction with activated T cells,
but rather suggests that paracrine secretion of IFN-y by T cells is
needed. Indeed, CD4pos and CD8pos T cells in the bonemarrow of
CD70TG mice were shown to produce high levels of IFN-y upon
measurement by FACS analysis (Arens et al., 2001). Remarkably,
systemic increase of IFN-y levels could not be measured in these
mice suggesting that the action of IFN-y on MSCs is mediated
when T cells and MSCs are in close proximity. In addition, upon
activation, T cells are able to produce VEGF-A (Matsuyama et al.,
2002). Whether VEGF-A production by activated T is under
the influence of IFN-y and abrogated in CD70TG/IFN-y−/− is
unknown but could explain the lack of mobilization in these mice,
despite an active T cell compartment.
The observation that adoptive transfer of WT T cells but not
IFN-y−/− T cells into CD70TGxCD27−/− resulted in decreased
MSC numbers in the bone marrow supports the hypothesis of
T cell mediated, IFN-y dependent reduction of MSCs. Shortly
after transfer, we were unable to observe differences between
CD70TGxCD27−/− mice that received WT T cells or IFN-y−/−
T cells indicating that only upon prolonged T cell activation and
IFN-y production by donor T cells, MSC numbers are reduced
from the bone marrow.
We did not observe increased cell death upon in vitro stim-
ulation of MSCs with IFN-y (data not shown), suggesting that
MSCs are resistant to IFN-y mediated apoptosis as was observed
to occur with B cells. Analysis of complete EAE bone marrow
samples upon in vitro restimulation with MOG did not reveal
increased IFN-y levels, suggesting that either antigen specific T
cells are suppressed or completely absent from the bone marrow
during EAE, or that IFN-y production by MOG-specific T cells
cannot be measured in the supernatants. Decreased effector func-
tions of T cells upon in vitro restimulation would be in line with
other publications showing that MSCs are able to inhibit T cell
activation (Zappia et al., 2005; Gerdoni et al., 2007; Kassis et al.,
2008). Therefore, the interaction between IFN-y producing T cells
and MSCs will critically control both cell subsets, since suppres-
sion of activated IFN-y producing T cells by MSCs may sustain
theMSC population in the bonemarrow, while loss of this control
will ensure their mobilization from the bone marrow.
It is unclear whether bone marrow MSCs that disappear from
the bone marrow during the disease, localize to distinct organs.
Based on CFU-F assays, we could observe MSCs in the meninges
of EAE mice at day 15 (data not shown). Although the numbers
of CFUs were very low, these colonies could never be observed in
control mice. Several studies indicate that upon systemic admin-
istration, MSCsmigrate to lymphoid organs as well as to the brain
and SPC (Zappia et al., 2005; Kassis et al., 2008). We did not
observe significant differences between MSCs present in SPCs of
diseased versus non-diseased mice, although this may need fur-
ther analysis at different timepoints. It could however be that
subsequent differentiation of MSCs within the affected tissue pre-
vents their CFU-F capacity in our assays, thus limiting our ability
to detect them.
The observation that bone marrow MSCs are mobilized from
the bone marrow at the peak of disease could have a similar
effect on the course of the disease as the therapeutic adminis-
tration of exogenous MSCs, which is most effective before or at
the peak of disease. These data suggests the need for a temporal
systemic increase of MSCs before clinical disease onset to sup-
press the priming and activation of autoimmune/antigen specific
T cells. Future studies that induce the active mobilization and
proliferation of endogenous bone marrow MSCs before onset of
clinical disease would indicate whether the endogenousMSCs can
dampen the effects of T cell mediated autoimmunity.
EXPERIMENTAL PROCEDURES
ANIMALS
EAE was induced in female FVB mice (NKI, Amsterdam)
or C57BL/6 (Charles River, France), 8–12 weeks of age and
housed at the VU University Medical Center. B cell-specific
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CD70TG (Arens et al., 2001), IFN-γ−/−, CD70TGxIFN-γ−/−,
CD70TGxCD27−/−, andwild-type control mice were housed and
used at the AMC, Amsterdam. All experimental procedures were
reviewed and approved by the Ethical Committee for Animal
Experiments of the VU (Vrije Universiteit) University Medical
Center (Amsterdam, The Netherlands).
INDUCTION OF EAE
EAE was induced in 8–12-week-old female mice via subcuta-
neous immunization with 200μg rMOG (1–125; synthesized
as described Adelmann et al., 1995) mixed (volume ratio 1:1)
with Complete Freund’s Adjuvant (CFA; Difco Laboratories) con-
taining 500μg of heat-killed Mycobacterium tuberculosis H37Ra
(MBT; Difco). Control (CFA) animals were injected with saline
mixed with CFA containing 500μg of heat-killed MBT. All
animals were additionally injected intraperitoneally (i.p.) with
200 ng pertussis toxin derived from Bordetella pertussis (Sigma,
Zwijndrecht, The Netherlands) in 200μL saline at the time of,
and 24 h after immunization. Mice were examined daily for clini-
cal signs of EAE and were scored as follows: 0, no disease; 1, limp
tail; 2, hind limb weakness; 3, complete hind limb paralysis; 4,
hind limb paralysis plus fore limb paralysis; and 5, moribund or
dead. Mice were euthanized at day 8, 15, or 29.
SINGLE CELL SUSPENSION
Bone marrow single cell suspensions were obtained according
to the following protocol. Freshly isolated femur and tibia were
flushed once with 1ml icecold DMEM (Gibco) supplemented
with 2% FCS, 2% antibiotics, and glutamine (Flush Fraction).
To release MSCs from the bone marrow, femur, and tibia were
subsequently incubated with DMEM containing Blendzyme 2
(150μg/ml), DNAse I (200 ug/ml, both Roche Applied Sciences,
The Netherlands), 2% FCS, and 2% antibiotics for 20min at 37◦C
under continuous stirring. After incubation, enzymatic activity
was stopped and femur and tibia were flushed once more with
1ml cold DMEM with 2% FCS and 2% antibiotics and all cells
were collected (Blendzyme 2 fraction).
Lymph node, SPC and meninges single cell suspension were
obtained as follows. Isolated cLNs, SPC, and meninges were
cut extensively into small pieces followed by enzymatic diges-
tion in DMEM containing Blendzyme 2 (150μg/ml), DNAse I
(200 ug/ml), 2% FCS, and 2% antibiotics for 15min at 37◦C
under continuous stirring. After incubation, enzymatic activity
was stopped by adding cold DMEM containing 10% FCS and 2%
antibiotics.
All single cell suspensions were washed once with an excess of
medium to remove any residual Blendzyme 2 and resuspended in
DMEM (Gibco) supplemented with 2% FCS, 2% antibiotics, and
glutamine, and cells were counted. For flow cytometry analysis,
cells were passed through a 70μm filter to remove cell clumps.
ADOPTIVE TRANSFER
T cells were obtained from lymph nodes and spleen single cell sus-
pensions from either WT (CD45.1pos) or IFN-y−/− mice. Single
cell suspensions were generated by mincing the organs through
40μm cell strainers followed by erythrocyte lysis with ACK lysis
buffer. Subsequently, cells were incubated with CD4 and CD8
microbeads (Miltenyi Biotec) and enriched by MACS positive
selection using automacs with LS columns (Miltenyi Biotec).
Enriched cells with a purity of >95% as determined by flow
cytometry, were resuspended in PBS and 5–10×106 in 200μl PBS
cells were intravenously injected into CD70TGxCD27−/− mice.
Mice were sacrificed and analyzed 5 days or 21 days after T cell
transfer.
COLONY FORMING UNIT ASSAY
Colony forming unit (CFU) assays were performed according
to the following protocol: single cell suspensions were seeded
at three different concentrations in 2ml Mesencult + stim-
ulatory supplements (Mesencult Proliferation Kit, Stem Cell
Technologies, France) and 2% antibiotics/well in a 6-wells plate.
CFU assays were always performed in duplo. After 2 weeks of
culture, adherent cells were washed twice with PBS, fixed in
methanol and stained with Giemsa. CFU’s were counted using
a stereo microscope. A cluster of cells containing ≥10 cells was
considered a colony.
FLOW CYTOMETRY
Single cell suspensions were seeded at 2 × 106 cells/well in a 96
well plate (4◦C). All cells were incubated with 10% (vol/vol)
normal mouse serum (NMS) to block aspecific binding of pri-
mary antibodies. Subsequently, staining with the appropriate
antibodies was carried out for 30min at 4◦C.
The following antibodies, recognizing CD45R (clone RA3-
6B2), CD8 (clone 53-6.7), and CD31 (clone ERMP12) were
affinity purified from the supernatants of hybridoma cell cultures
by using protein G-sepharose (Pharmacia, Uppsala, Sweden).
The antibodies were either biotinylated or labeled with Alexa-
Fluor-488 or Alexa-Fluor-647 (Invitrogen Life Technologies).
Unless stated otherwise, the following antibodies were obtained
from eBioscience; CD8-FITC (clone Ly-2), CD45.1-FITC (BD
Biosciences, Clone A20), GR-1-Alexa-Fluor-488 (clone RB6-
8C5), CD8-PE (clone Ly-2), CD19-PE (BD Pharmingen clone
ID3), CD44-PE (clone IM-7), F4/80-PE (clone BM8), SCA-1
PE-Cy5.5 (clone D7), CD45-PE-Cy7 (clone 30F-11), CD4-APC
(clone GK1.5), CD62L-APC (clone MEL-14) IFN-y-APC (clone
XMG1.2), CD11c-APC (clone N418), CD45 Pacific Orange
(Caltag Laboratories, clone 30-F11), and CD11b-biotinylated
(Beckman Coulter, clone M1/70). Biotinylated antibodies were
visualized with Streptavidin-APC-Cy7 (eBioscience). Sytox Blue
dead cell stain (Molecular Probes) was used to discriminate
between live and dead cells. Data were acquired on a Cyan ADP
High Performance Research Flow Cytometer (Beckman Coulter)
and were analyzed with Summit Software v4.3. Single stained cells
were used to compensate for spectral overlap. FluorescenceMinus
One (FMO) stained cells were used to set boundaries between
positively and negatively stained cells.
In vitro RESTIMULATION AND LUMINEX ASSAY
Bone marrow single cell suspensions were seeded at 1 × 106
cells/well in a flat-bottomed 96 well plate in media [IMDM
supplemented with 10% FCS, 50μM β-mercaptoethanol, 2%
penicillin, streptomycin, and L-glutamine (PSG)]. Cells were
stimulated with either various concentrations (3–30μg/ml)
www.frontiersin.org March 2013 | Volume 4 | Article 49 | 9
Koning et al. Inflammation mobilizes bone-marrow stromal precursors
rMOG (1–125) or PMA (20 ng/ml; Sigma)/ionomycin
(500 ng/ml; Sigma) as a positive control. Supernatants were
harvested after 72 h and stored in −20◦C until further analy-
sis. IFN-y, IL-17, TNF-α, VEGF, and GM-CSF were measured
using Luminex assay (Millipore Corporation, USA, cat.nr.
mpxmcyto-70k) according to the manufacturer’s instructions.
For in vitro restimulation of bone marrow T cells, 1 × 106
total bone marrow cells were restimulated for 6 h with PMA
(10 ng/ml) and Ionomycin (1μM) in the presence of Brefeldin A
(Golgiplug™, BD biosciences). The percentage of IFN-y produc-
ing T cells was measured with flow cytometry.
In vitro MSC PROLIFERATION
Bone marrow single cell suspensions from healthy C57BL/6 mice
were obtained as described above. To expand MSCs in vitro,
bone marrow single cell suspensions were cultured overnight
in Mesencult + stimulatory supplements and 2% antibiotics.
After 24 h, non-adherent cells were removed and fresh medium
was added. After two passages, cells were used for prolifera-
tion assays. Hereto, cells were harvested upon trypsinization and
washed extensively with PBS. Cells were labeled with 5μM 5,6-
carboxyfluorescein succinimidyl ester (CFSE, Moleculare Probes,
Invitrogen) at 1 × 107 cells/ml for 10min at 37◦C. After washing,
the cells were seeded at 0.1 × 106 cells per well in a 6-wells plate
supplemented with 2ml Mesencult + stimulatory supplements.
Cells were allowed to adhere for 2 h and subsequently incubated
with the following stimuli at various concentrations (0.25 ng/ml,
2.5 ng/ml, and 25 ng/ml); IL-1, IL-6, IL-10, IL-17, IFN-y, TNF-α,
G-CSF, GM-CSF, VEGF, and TGF-β (all peprotech, UK).
T cell conditioned medium was prepared as follows; spleens
were isolated from C57BL/6 mice and minced through 70μm
gauze to obtain single cell suspensions. Red blood cells (RBCs)
were removed with lysis buffer (150mM NH4, 1mM NaHCO3,
pH 7.4). CD4 or CD8 T cells were labeled with either CD4-
PE-Cy7 (clone GK1.5) or CD8-PE-Cy7 (clone 53-6.7) antibodies
(both eBioscience) and isolated with the Easysep Mouse PE
Positive selection kit (Stem Cell Technologies, France) according
to manufacturer’s instructions. Purity was checked by flowcytom-
etry (>95% purity). Subsequently, purified T cells were stimu-
lated with CD3/CD28 beads (BD Bioscience) and after 72 h, T
cell conditioned supernatants were collected and stored at−20◦C.
For bone marrow MSC proliferation assay, T cell conditioned
medium was diluted 1:2, 1:5, or 1:10 and added to plate adher-
ent MSCs. For all proliferation assays, unstimulated CFSE labeled
cells were used as controls. After 72 h, cells were harvested by
trypsinization and CFSE dilution was analyzed on a Cyan ADP
as a measurement for proliferation. Sytox Blue dead cell staining
was used to discriminate between live and dead cells.
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